A flavonoid antioxidant, silymarin, inhibits activation of erbB1 signaling and induces cyclin-dependent kinase inhibitors, G1 arrest, and anticarcinogenic effects in human prostate carcinoma DU145 cells1

Cancer Research

Volumn 58, Issue 9, 1998, Pages 1920-1929

  Zi, Xiaolin ^a   Grasso, Adam W ^a   Kung, Hsing Jien ^a   Agarwal, Rajesh ^a,b  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF COLORADO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; SILYMARIN;

ARTICLE; CANCER CELL CULTURE; CELL CYCLE; CELL GROWTH; GROWTH INHIBITION; HUMAN; HUMAN CELL; MALE; MITOSIS INHIBITION; PRIORITY JOURNAL; PROSTATE CARCINOMA;

ANTIOXIDANTS; BLOTTING, WESTERN; CELL DIVISION; CYCLIN-DEPENDENT KINASES; FLOW CYTOMETRY; G1 PHASE; HUMANS; MALE; PROSTATIC NEOPLASMS; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION; SILYMARIN; TUMOR CELLS, CULTURED;

EID: 0032080609     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (75)

1. Hsing, A. W. Essential fatty acids and prostate cancer: an emerging hypothesis? Cancer Epidemiol. Biomark. Prev., 5: 859-860, 1996.
2. Godley, P. A., Campbell, M. K., Gallagher, P., Martinson, F. E. A., Mohler, J. L., and Sandler, R. S. Biomarkers of essential fatty acid consumption and risk of prostate carcinoma. Cancer Epidemiol. Biomark. Prev., 5: 889-895, 1996.
3. Parker, S. L., Tang, T., Bolden, S., and Wingo, P. A. Cancer Statistics, 1997. CA Cancer J. Clin., 47: 5-27, 1996.
4. Ross, R. K., and Henderson, B. E. Do diet and androgens alter prostate cancer risk via a common etiologic pathway? J. Natl. Cancer Inst., 86: 252-254, 1994.
5. Giovannucci, E., Rimm, E. B., Colditz, G. A., Stampfer, M. J., Ascherio, A., Chute, C. C., and Willett, W. C. A prospective study of dietary fat and risk of prostate cancer. J. Natl. Cancer Inst., 85: 1571-1579, 1993.
6. Gann, P. H., Hennekens, C. H., Sacks, F. M., Grodstein, F., Giovannucci, E. L., and Stampfer, M. J. Prospective study of plasma fatty acids and risk of prostate cancer. J. Natl. Cancer Inst., 86: 281-286, 1994.
7. Wynder, E. L., Rose, D. P., and Cohen, L. A. Nutrition and prostate cancer: a proposal for dietary intervention. Nutr. Cancer, 22: 1-10, 1994.
8. Karp, J. E., Chiarodo, A., Brawley, O., and Kelloff, G. J. Prostate cancer prevention: investigational approaches and opportunities. Cancer Res., 56: 5547-5556, 1996.
9. Levitzki, A., and Gazit, A. Tyrosine kinase inhibition: an approach to drug development. Science (Washington DC), 267: 1782-1788, 1995.
10. Kelloff, G. J., Fay, J. R., Steele, V. E., Lubet, R. A., Boone, C. W., Crowell, J. A., and Sigman, C. C. Epidermal growth factor receptor tyrosine kinase inhibitors as potential cancer chemopreventives. Cancer Epidemiol. Biomark. Prev., 5: 657-666, 1996.
11. Bostwick, D. G. c-erbB-2 oncogene expression in proslatic intraepithelial neoplasia: mounting evidence for a precursor role. J. Natl. Cancer Inst., 86: 1108-1110, 1994.
12. Myers, R. B., Srivastava, S., Oelschlager, D. K., and Grizzle, W. E. Expression of p160erbB3 and p185erbB2 in prostatic intraepithelial neoplasia and prostatic adenocarcinoma. J. Natl. Cancer Inst., 86: 1140-1145, 1994.
13. Pretlow, T. G., Pelley, R. J., and Pretlow, T. P. Biochemistry of prostatic carcinoma. In: T. G. Pretlow and T. P. Pretlow (eds.), Biochemical and Molecular Aspects of Selected Cancers, pp. 169-237, San Diego: Academic Press, 1994.
14. Bostwick, D. G., and Aquilina, J. W. Prostatic intraepithelial neoplasia (PIN) and other prostatic lesions as risk factors and surrogate endpoints for cancer chemoprevention trials. J. Cell. Biochem., 25 (Suppl.): 156-164, 1996.
15. Ware, J. L. Growth factors and their receptors as determinants in the proliferation and metastasis of human prostate cancer. Cancer Metastasis Rev., 12: 287-301, 1993.
16. Hofer, D. R., Sherwood, E. R., Bromberg, W. D., Mendelsohn, J., Lee, C., and Kozlowski, J. M. Autonomous growth of androgen-independent human prostatic carcinoma cells: role of transforming growth factor α. Cancer Res., 51: 2780-2785, 1991.
17. Fong, C. J., Sherwood, E. R., Mendelsohn, J., Lee, C., and Kozlowski, J. M. Epidermal growth factor receptor monoclonal antibody inhibits constitutive receptor phosphorylation, reduces autonomous growth, and sensitizes androgen-independent prostatic carcinoma cells to tumor necrosis factor α. Cancer Res., 52: 5887-5892, 1992.
18. 1 arrest in prostatic carcinoma cell line DU145. Cancer Res., 56: 3666-3669, 1996.
19. Bostwick, D. G., Burke, H. B., Wheeler, T. M., Chung, L. W. K., Bookstein, R., Pretlow, T. G., Nagle, R. B., Montirino, R., Lieber, M. M., Veltri, R. W., Grizzel, W. E., and Grignon, D. J. The most promising surrogate endpoint biomarkers for screening candidate chemopreventive compounds for prostatic adenocarcinoma in short-term Phase II clinical trials. J. Cell. Biochem. Suppl., 19: 283-289, 1994.
20. Boone, C. W., Kelloff, G. J., and Malone, W. E. Identification of candidate cancer chemopreventive agents and their evaluation in animal models and human clinical trials. Cancer Res., 50: 2-9, 1990.
21. Boone, C. W., and Wattenberg, L. W. Current strategies of cancer chemoprevention: 13th Sapporo Cancer Seminar. Cancer Res., 54: 3315-3318, 1994.
22. Wattenberg, L. W. Inhibition of carcinogenesis by minor dietary constituents. Cancer Res., 52 (Suppl.): 2085s-2091s, 1992.
23. Morse, M. A., and Stoner, G. D. Cancer chemoprevention: principles and prospects. Carcinogenesis (Lond.), 14: 1737-1746, 1993.
24. Kelloff, G. J., Boone, C. W., Crowell, J. A., Steele, V. E., Lubet, R., and Sigman, C. C. Chemopreventive drug development: prospectives and progress. Cancer Epidemiol. Biomark. Prev., 3: 85-98, 1994.
25. Ames, B. N., Gold, L. S., and Willett, W. C. The causes and prevention of cancer. Proc. Natl. Acad. Sci. USA, 92: 5258-5265, 1995.
26. Bostwick, D. G., Scardino, P. T., Kelloff, G. J., and Boone, C. W. Chemoprevention of premalignant and early malignant lesions of the prostate. J. Cell. Biochem. Suppl., 16H: 1-145, 1992.
27. Boone, C. W., and Kelloff, G. J. Qualitative pathology in chemoprevention trails: standardization and quality control of surrogate endpoint biomarker assays for colon, breast, and prostate. J. Cell. Biochem. Suppl., 19: 1-294, 1994.
28. Kelloff, G. J., Boone, C. W., Crowell, J. A., Nayfield, S. G., Hawk, E., Malone, W. F., Steele, V. E., Lubet, R. A., and Sigman, C. C. Risk biomarkers and current strategies for cancer chemoprevention. J. Cell. Biochem., 25S: 1-14, 1996.
29. Brawer, M. K., and Ellis, W. J. Chemoprevention for prostate cancer. Cancer (Phila.) Suppl., 75: 1783-1789, 1995.
30. Agarwal, R., and Mukhtar, H. Cancer chemoprevention by polyphenols in green tea and artichoke. In: Advances in Experimental Medicine and Biology: Dietary Phytochemicals in Cancer Prevention and Treatment, pp. 35-50, Vol. 401. New York: Plenum Press, 1996.
31. Mereish, K. A., Bunner, D. L., Ragland, D. R., and Creasia, D. A. Protection against microcystin-LR-induced hepatotoxicity by silymarin: biochemistry, histopathology, and lethality. Pharmacol. Res., 8: 273-277, 1991.
32. Letteron, P., Labbe, G., Degott, C., Berson, A., Fromenty, B., Delaforge, M., Larrey, D., and Pessayre, D. Mechanism for the protective effects of silymarin against carbon tetrachloride-induced lipid peroxidation and hepatotoxicity in mice. Biochem. Pharmacol., 39: 2027-2034, 1990.
33. Ferenci, P., Dragosics, B., Dittrich, H., Frank, H., Benda, L., Lochs, H., Meryn, S., Base, W., and Schneider, B. Randomized controlled trial of silymarin treatment in patients with cirrhosis of the liver. J. Hepatol., 9: 105-113, 1989.
34. 4-induced liver cirrhosis by silymarin. Fundam. Clin. Pharmacol., 3: 183-191, 1989.
35. Vogel, G., Trost, W., and Braatz, R. Studies on the pharmacodynamics, including site and mode of action, of silymarin: the antihepatotoxic principle from Silybum mar. (L) Gaertn. Arzneim. Forsch., 25: 82-89, 1975.
36. Hahn, V. G., Lehmann, H. D., Kurten, M., Uebel, H., and Vogel, G. Pharmacology and toxicology of silymarin, the anti-hepatotoxic agent of Silybum marianum (L.) Gaertn. Arzneim. Forsch., 18: 698-704, 1968.
37. Ely, H. Dermatologic therapies you've probably never heard of. Derm. Clinics, 7: 19-35, 1989.
38. Wagner, H., Seligmann, O., Horhammer, L., and Munster, R. The chemistry of silymarin (silybin), the active principle of the fruits of Silybum marianum (L.) Gaertn (Carduus marianus (L)). Arzneim. Forsch., 18: 688-696, 1968.
39. Bosisio, E., Benelli, C., and Pirola, O. Effect of the flavanolignans of Silybum marianum L. on lipid peroxidation in rat liver microsomes and freshly isolated hepatocytes. Pharmacol. Res., 25: 147-154, 1992.
40. Carini, R., Comoglio, A., Albano, E., and Poli, G. Lipid peroxidation and irreversible damage in the rat hepatocyte model. Protection by the silybin-phospholipid complex IdB 1016. Biochem. Pharmacol., 43: 2111-2115, 1992.
41. Racz, K., Feher, J., Csomos, G., Varga, I., Kiss, R., and Glaz, E. An antioxidant drug, silibinin, modulates steroid secretion in human pathological adrenocortical cells. J. Endocrinol., 124: 341-345, 1990.
42. Valenzuela, A., Guerra, R., and Videla, L. A. Antioxidant properties of the flavonoids silybin and (+)-cyanidanol-3: comparison with butylated hydroxyanisole and butylated hydroxytoluene. Planta Med., 5: 438-440, 1986.
43. Comoglio, A., Leonarduzzi, G., Carini, R., Busolin, D., Basaga, H., Albano, E., Tomasi, A., Poli, G., Morazzoni, P., and Magistretti, M. J. Studies on the antioxidant and free radical scavenging properties of IdB 1016 a new flavanolignan complex. Free Radical Res. Commun., 11: 109-115, 1990.
44. Muzes, G., Deak, G., Lang, I., Nekam, K., Gergely, P., and Feher, J. Effect of the bioflavonoid silymarin on the in vitro activity and expression of superoxide dismutase (SOD) enzyme. Acta Phys. Hung., 78: 3-9, 1991.
45. Agarwal, R., Katiyar, S. K., Lundgren, D. W., and Mukhtar, H. Inhibitory effect of silymarin, an anti-hepatotoxic flavonoid, on 12-O-tetradecanoylphorbol-13-acetate-induced epidermal ornithine decarboxylase activity and mRNA in SENCAR mice. Carcinogenesis (Lond.), 15: 1099-1103, 1994.
46. Katiyar, S. K., Korman, N. J., Mukhtar, H., and Agarwal, R. Protective effects of silymarin against photocarcinogenesis in mouse skin model. J. Natl. Cancer Inst., 89: 556-566, 1997.
47. Zi, X., Mukhtar, H., and Agarwal, R. Novel cancer chemopreventive effects of a flavonoid antioxidant silymarin: inhibition of mRNA expression of an endogenous tumor promoter TNFα. Biochem. Biophys. Res. Commun., 239: 334-339, 1997.
48. Mehta, R. G., and Moon, R. C. Characterization of effective chemopreventive agents in mammary gland in vitro using an initiation-promotion protocol. Anticancer Res., 11: 593-596, 1991.
49. 1 arrest mediated by an anti-epidermal growth factor receptor monoclonal antibody. Oncogene, 12: 1397-1403, 1996.
50. Canman, C. E., and Kastan, M. B. Three paths of stress relief. Nature (Lond.), 384: 213-214, 1996.
51. Rosette, C., and Karin, M. Ultraviolet light and osmotic stress: activation of the JNK cascade through multiple growth factor and cytokine receptors. Science (Washington DC), 274: 1194-1197, 1996.
52. Irani, K., Xia, Y., Zweier, J. L., Sollott, S. J., Der, C. J., Fearon, E. R., Sundaresan, M., Finkel, T., and Clermont, P. J. G. Mitogenic signaling mediated by oxidants in ras-transformed fibroblasts. Science (Washington DC), 275: 1649-1652, 1997.
53. Carpenter, G., and Cohen, S. Epidermal growth factor. J. Biol. Chem., 265: 7709-7712, 1990.
54. Das, R., and Vonderhaar, B. K. Involvement of SHC, GRB2, SOS and RAS in prolactin signal transduction in mammary epithelial cells. Oncogene, 13: 1139-1145, 1996.
55. Nakamura, T., Sanokawa, R., Sasaki, Y., Ayusawa, D., Oishi, M., and Mori, N. N-Shc: a neural-specific adapter molecule that mediates signaling from neurotrophin/ Trk to Ras/MAPK pathway. Oncogene, 13: 1111-1121, 1996.
56. Hunter, T., and Pines, J. Cyclins and cancer II: cyclin D and CDK inhibitors come of age. Cell, 79: 573-582, 1994.
57. Morgan, D. O. Principles of CDK regulation. Nature (Lond.), 374: 131-134, 1995.
58. Liu, Y., Martindale, J. L., Gorospe, M., and Holbrook, N. J. Regulation of p21WAF1/ CIP1 expression through mitogen-activated protein kinase signaling pathway. Cancer Res., 56: 31-35, 1996.
59. WAF1/CIP1, Rb, and c-myc signaling in phorbol ester-resistant cancer cells. Cancer Res., 57: 320-325, 1997.
60. Grana, X., and Reddy, P. Cell cycle control in mammalian cells: role of cyclins, cyclin dependent kinases (CDKs), growth suppressor genes and cyclin-dependent kinase inhibitors (CDKIs). Oncogene, 11: 211-219, 1995.
61. Barnes, S., Peterson, T. G., and Coward, L. Rationale for the use of genistein-containing soy matrices in chemoprevention trials for breast and prostate cancer. J. Cell. Biochem. Suppl., 22: 181-187, 1995.
62. Messina, M. J., Persky, V., Setchell, K. D. R., and Barnes, S. Soy intake and cancer risk: a review of the in vitro and in vivo data. Nutr. Cancer, 21: 113-131, 1994.
63. Umekita, Y., Hiipakka, R. A., Kokontis, J. M., and Liao, S. Human prostate tumor growth in athymic mice: inhibition by androgens and stimulation by finasteride. Proc. Natl. Acad. Sci. USA, 93: 11802-11807, 1996.
64. Ripple, M. O., Henry, W. F., Rago, R. P., and Wilding, G. Prooxidant-antioxidant shift induced by androgen treatment of human prostate carcinoma cells. J. Natl. Cancer Inst., 89: 40-48, 1997.
65. Aquilina, J. W., Lipsky, J. J., and Bostwick, D. G. Androgen deprivation as a strategy for prostate cancer chemoprevention. J. Natl. Cancer Inst., 89: 689-696, 1997.
66. Tilley, W. D., Wilson, C. M., Marcelli, M., and McPhaul, M. J. Androgen receptor gene expression in human prostate carcinoma cell lines. Cancer Res., 50: 5382-5386, 1990.
67. Scher, H., Sarkis, A., Reuter, V., Cohen, D., Netto, G., Petrylak, D., Lianes, P., Fuks, Z., Mendelsohn, J., and Cordon-Cardo, C. Changing pattern of expression of the epidermal growth factor receptor and transforming growth factor α in the progression of prostatic neoplasms. Clin. Cancer Res., 1: 545-550, 1995.
68. Weinstein, I. B. relevance of cyclin D1 and other molecular markers to cancer chemoprevention. J. Cell. Biochem., 25S: 23-28, 1996.
69. Draetta, G. Cell cycle control in eukaryotes: molecular mechanisms of cdc2 activation. Trends Biochem. Sci., 15: 378-383, 1990.
70. Pines, J., and Hunter, T. Human cyclin A is adenovirus E1A-associated protein p60 and behaves differently from cyclin B. Nature (Lond.), 346: 760-763, 1990.
71. 1 phase progression: cycling on cue. Cell, 79: 551-555, 1994.
72. 1. Genes Dev., 7: 812-821, 1993.
73. 1-to-S transition in mammalian cells. Oncogene, 8: 1593-1602, 1993.
74. 1-to-S phase transition. Mol. Cell. Biol., 15: 2612-2624, 1995.
75. 1 cyclin-dependent kinases. Genes Dev., 9: 1149-1163, 1995.